AXNX vs. CMD, NUVA, ATRC, CSII, SILK, PODD, SWAV, TFX, SOLV, and GMED
Should you be buying Axonics stock or one of its competitors? The main competitors of Axonics include Cantel Medical (CMD), NuVasive (NUVA), AtriCure (ATRC), Cardiovascular Systems (CSII), Silk Road Medical (SILK), Insulet (PODD), Shockwave Medical (SWAV), Teleflex (TFX), Solventum (SOLV), and Globus Medical (GMED). These companies are all part of the "medical" sector.
Cantel Medical (NYSE:CMD) and Axonics (NASDAQ:AXNX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
Cantel Medical received 37 more outperform votes than Axonics when rated by MarketBeat users. However, 66.92% of users gave Axonics an outperform vote while only 65.53% of users gave Cantel Medical an outperform vote.
Cantel Medical has higher revenue and earnings than Axonics. Axonics is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.
Cantel Medical has a net margin of 4.72% compared to Cantel Medical's net margin of -4.12%. Axonics' return on equity of 12.13% beat Cantel Medical's return on equity.
Cantel Medical has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Axonics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
In the previous week, Axonics had 4 more articles in the media than Cantel Medical. MarketBeat recorded 4 mentions for Axonics and 0 mentions for Cantel Medical. Cantel Medical's average media sentiment score of 1.82 beat Axonics' score of 0.00 indicating that Axonics is being referred to more favorably in the news media.
Axonics has a consensus target price of $70.30, suggesting a potential upside of 4.80%. Given Cantel Medical's higher probable upside, analysts clearly believe Axonics is more favorable than Cantel Medical.
84.1% of Cantel Medical shares are owned by institutional investors. Comparatively, 99.5% of Axonics shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by insiders. Comparatively, 1.9% of Axonics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Cantel Medical beats Axonics on 10 of the 17 factors compared between the two stocks.
Get Axonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
